A 31-yr-old man presented with a 1-wk history of fever, chills, weakness, headaches, and a significant 20-lb weight loss over the preceding 2 months. His past medical history was relevant for liver amebiasis during childhood. Two days before admission, the patient noticed jaundice. He denied abdominal pain or other GI symptoms, and there was no history of alcohol intake, medications, or illicit drugs. His physical examination revealed generalized jaundice, hepatosplenomegaly, and bilateral leg edema. Neurologically, the patient was agitated, with periods of disorientation, and he had bilateral flapping. His blood tests revealed pancytopenia, renal failure, liver failure, and coagulopathy. Because the patient had a fever, hepatosplenomegaly, and pancytopenia, a further workup also included a bone marrow and liver biopsy. No conclusive diagnosis could be made from the above tests, and the patient died 5 days after admission. Postmortem evaluation, including flow cytometry and gene rearrangement in the tissue obtained from the liver, revealed large B cell lymphoma. This case illustrates an unusual presentation of hepatic non-Hodgkin's lymphoma. Current information regarding this entity is scant, mainly owing to its rarity. We present a review of the literature, including the incidence, presentation, treatment, and prognosis of primary hepatic lymphoma.
Summary:There are few reports describing the association between antiphospholipid antibodies, including the lupus anticoagulant, and bone marrow or peripheral stem cell transplantation. Autoimmune syndromes and autoantibodies such as lupus anticoagulant and anticardiolipin antibodies have been described following allogeneic bone marrow or peripheral blood stem cell transplantation, particularly in patients who develop chronic graft-versushost disease (GVHD). The association between Lupus anticoagulant and acute GVHD has not been previously described. We report a patient who developed a de novo lupus anticoagulant on day +34 after a matched-related allogeneic peripheral stem cell transplant. No clinical evidence of systemic thrombosis was observed and the lupus anticoagulant disappeared following immunosuppressive therapy with a combination of steroids and infliximab. Bone Marrow Transplantation (2003) 31, 129-131. doi:10.1038/sj.bmt.1703794 Keywords: lupus anticoagulant; acute GVHD; bone marrow transplantation; peripheral stem cell transplantation When allogeneic bone marrow or peripheral stem cells are the source of stem cells, donor-derived T cells recognize and react to histoincompatible recipient antigens and cells, a phenomenon that forms the basis for the development of graft-versus-host disease (GVHD). 1 GVHD remains a major complication of allogeneic bone marrow and peripheral stem cell transplantation (BM/PSCT). Autoimmune syndromes and autoantibodies including lupus anticoagulant and anticardiolipin antibodies have been described following allogeneic BM/PSCT, particularly in patients who develop chronic GVHD. 2,3 The lupus anticoagulant is an antibody that binds to a complex of anionic phospholipid-bound prothrombin, resulting in prolongation of phospholipid-dependent clotting times. 4 Newly acquired lupus anticoagulant has been reported in association with chronic GVHD, 5 but not with acute GVHD (aGVHD). We report a case of an acquired lupus anticoagulant that developed on day +34 after a matchedrelated allogeneic peripheral stem cell transplant. Case reportA 28-year-old man diagnosed with aplastic anemia received a matched-related allogeneic PSCT. The conditioning regimen included cyclophosphamide at a daily dose of 50 mg/ kg on days À5 to À2 and antithymocyte globulin (ATG) at a dose of 30 mg/kg administered on days À4 to À2, given 12 h after cyclophosphamide. Immunosuppression consisted of tacrolimus at a dose of 0.03 mg/kg daily and methotrexate at a dose of 10 mg/m 2 on day +1 and 5 mg/m 2 on days +3, +6 and +11. The patient's immediate post-transplant course was uneventful with engraftment on day +16 and discharge from the unit on day +24. The patient presented to the bone marrow transplant unit on day +34 with symptoms suggestive of gastrointestinal aGVHD including abdominal pain and bloody diarrhea. Biopsy of the colon confirmed the diagnosis. Additional laboratory examination disclosed an isolated prolongation of the aPTT of 82.7 s (normal range: 23.8-32.2 s). The baseline value of the patien...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.